Brief: Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
04/06/2024 13:45
June 4 (Reuters) - Surrozen Inc SRZN.O :
* SURROZEN INITIATES DOSING OF FIRST PATIENT IN PHASE 1B
CLINICAL
TRIAL OF SZN-043 FOR SEVERE ALCOHOL-ASSOCIATED HEPATITIS
* SURROZEN INC - ANTICIPATE POTENTIAL PROOF-OF-CONCEPT DATA
AVAILABLE IN FIRST HALF OF 2025
* SURROZEN : SZN-043 CLINICAL TRIAL PROGRAM IN SEVERE
ALCOHOL-ASSOCIATED HEPATITIS & ANTICIPATE THAT PROOF-OF-CONCEPT
DATA MAY BE AVAILABLE IN H1 2025
Source text for Eikon: ID:nGNX5DQGyq
Further company coverage: SRZN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surrozen
See all newsBrief: Surrozen Announces Closing Of Second Tranche Of March 2025 Private Placement For $95.1 Million
Surrozen, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Surrozen Q2 Operating Income USD -10.37 Million
Surrozen, Inc. expected to post a loss of $1.29 a share - Earnings Preview
Brief: Surrozen Q1 EPS USD -11.65